VEGFA and wet macular degeneration: The emergence of anti-vascular endothelial growth factor (VEGF) agents has led to a significant reduction in visual impairment from neovascular age-related macular degeneration (nAMD)8, and ranibizumab and aflibercept are the two approved drugs.